COVID-19 Update

Non-Clinicians / Medical Office Support Staff / Industry Participants

Due to the global COVID-19 pandemic and rapidly evolving public health organization guidance pertaining to its response, PAINWeek has made the decision to postpone the St. Louis PAINWeekEnd scheduled for April 18.

As you are undoubtedly aware, the Centers for Disease Control and Prevention (CDC) has recommended that in-person events comprising 50 or more attendees not be held for the next 8 weeks. Concurrently, various state and local authorities have begun directing the closure of bar, restaurant, and public service establishments in their jurisdictions. In view of the critical importance of these and other social distancing measures to attenuate the spread of infection and its impact on the healthcare system, we believe this postponement of our upcoming conferences is unavoidably necessary. A revised schedule for this conference will be developed and provided as soon as possible. Your registration will automatically transfer to the new date; however, you may request an immediate refund of your registration fee if you prefer.

If you made airline reservations, we recommend that you contact the airline to cancel. Most major carriers have added flexible change and cancellation policies. If you had plans to stay overnight, please contact the hotel directly to cancel your reservation.

We greatly regret the impact of this postponement on our attendees’ professional schedules and their interest in pain management education. As primary care practitioners, many of you are truly on the front lines of patient care in your communities, now more than ever in this uncertain time.

We are looking into adding more virtual and distance learning options. In the meantime, if you haven’t already done so, we recommend visiting the online education section of our website that includes articles, videos, interviews with thoughts leaders, and our PAINWeek Journal. We have also recently posted a webcourse entitled "Understanding and Addressing the Global Spread of the COVID-19 Infection: A Clinician's Guide" that is certified for 1-hour of CME/CE credit.

Please contact us with any questions or issues pertaining to your registration. Please accept our thanks for your understanding and support.

Saturday, May 30, 2020

  • REGISTRATION & EXHIBITS

    Coffee will be served.

  • Neck and Upper Extremity Pain Syndromes

    There are many potential underlying causes for neck and upper extremity pain. All too often, only the most common conditions, such as a disk herniation centrally or carpal tunnel syndrome, are explored. The purpose of this course is to review other common problems such as radiculitis, and not so common such as rib arthropathy pain syndromes that can affect the neck and upper extremities. Attention will be given to clinical pearls for recognizing when patients present with such problems, as well as treatments that may prove helpful for both differentially diagnosing and treating various neck and upper extremity pain syndromes, especially many of those that are often missed or overlooked and easily treatable to resolution when they are identified.

    • UAN: 0530-0000-20-055-L01-P
    • AANP Rx Hours: 0.00
  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Breakfast will be served.

    *This session is not certified for credit.

  • BREAK & EXHIBITS

  • Nonopioid Analgesics, Adjuvants, and Antidepressants

    Nonopioid analgesics are considered first-line therapy for most chronic pain syndromes. A strong recall of these agents’ safety and efficacy profiles is paramount for today’s pain practitioner. This course will provide an in-depth look at each of the agents within these drug classes, their potential role in pain management, and available data supporting their use. Additionally, clinically relevant monitoring will be discussed.

    • UAN: 0530-0000-20-030-L01-P
    • AANP Rx Hours: 1.00
  • The Gang That Couldn't Shoot Straight: Reconsidering the CDC Guideline

    After last year’s talk about the CDC Guideline, a lot has begun to change, begrudgingly. While this is encouraging, there are still both medical and nonmedical people who don’t want to see any changes in the weak to very weak (evidenced-based medicine) CDC Guideline, which has gone far from what it was supposed to be—recommendations for treatment in a primary care providers clinic. They have been “taken over, mandatorily” by a number of significant entities including CMS, various states, and more. Still, there appear to be political and nonpolitical but nonmedical mandated issues that continue to keep these “Guideline” in force. This presentation will discuss these and some possible reasons, both the positive and the negative, including important issues of forced tapering and increased suicides.

    • UAN: 0530-0000-20-056-L01-P
    • AANP Rx Hours: 0.90
  • FACULTY Q&A

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Lunch will be served.

    Sponsored by AstraZeneca-Daiichi Sankyo, Inc.

    *This session is not certified for credit.

  • Back Pain: It's All About the Diagnosis

    The prevalence of back pain continues in spite of the many treatments available, without any single treatment being a panacea. In routine clinical practice there has been a tendency of clinical examinations to become more cursory, largely influenced by increasing demands of time and arguably an overreliance upon technology. It has been suggested that the failure to adequately differentially diagnose the cause of back pain can account for clinical failures in treatment. The purpose of this discussion is to assist clinicians in the development of a more specific problem focused examination to enhance the differential diagnosis of specific pain generators, and therefore lead to more patient specific treatment. Attention will be given to considering all aspects of the examination, including physical assessment as well as imaging studies, and the ability to rationalize when pathologies seen on imaging studies may or may not be clinically significant. The importance of considering how failed treatments influence the differential diagnosis will also be discussed.

    • UAN: 0530-0000-20-053-L01-P
    • AANP Rx Hours: 0.00
  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Refreshments will be served.

    *This session is not certified for credit.

  • What's All the "GABA" About? Pregabalin and Gabapentin Abuse

    The gabapentinoids are a popular class of medications among prescribers for use in chronic pain and various other neurological conditions. In fact, prescription rates for both gabapentin and pregabalin have increased in the United States and other countries in recent years. However, these medications have a street value to a newer niche of users, including patients taking them at megadoses to enhance the effects of other psychotropic drugs, and other patients taking them to manage or mitigate opioid withdrawal symptoms and possibly even opioid cravings. While pregabalin is already classified as a controlled substance, gabapentin does not yet carry this classification. In response to rising abuse, various states and regulatory bodies are considering changes to enhance patient safety and protect the provider’s license. Learn what changes you should make to your practice, if any, in light of the growing abuse of gabapentinoids and how to identify patients potentially abusing them.

    • UAN: 0530-0000-20-036-L01-P
    • AANP Rx Hours: 0.00
  • Migraines and More

    During this course, we will go over the clinical symptomatology of migraine in a number of its various forms, as well as the pathophysiology of migraine. Also examined will be the acute as well as prophylactic treatment of migraine using evidence based criteria.

    • UAN: 0530-0000-20-054-L01-P
    • AANP Rx Hours: 0.20

SPONSORED PROGRAMS